Elicio Therapeutics, Inc. (ELTX) income statement
ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.59+0.16 (+11.19%)
Close on Nov 18, 2026Market cap $41.79MP/E –Yield –
Elicio Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- 817.9%
Financial strength
- Current ratio
- 2.77
- Debt to equity
- 1.20
- Debt to assets
- 30.4%
- Cash to current liabilities
- 255.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.26
- Dividend yield
- –
See a number that looks wrong?